SUMMARY As'a side project to a study of coronary risk factors 4878 men and women aged were interviewed about present and previous use of antihypertensive drugs. Serum lipid and glucose concentrations were compared in 124 present users, 73 previous users, and 124 controls matched for age, sex, and systolic and diastolic blood pressure. Users of betablockers, thiazides, and other antihypertensive drugs had higher total cholesterol, triglycerides, and glucose and lower HDL-cholesterol than the other groups, but only the difference in HDL-cholesterol was statistically significant. Smokers had statistically significant lower HDL-cholesterol than non-smokers in drug users, whereas there were only minor differences between them in previous and never users. This indicates an interaction between smoking and current antihypertensive medication. The unfavourable serum lipid pattern may, if caused by drug use, explain the lack of influence that antihypertensive treatment has had on the incidence of coronary heart disease in intervention studies.
Drug treatment of hypertension has often failed to decrease the incidence of coronary heart disease and total mortality.' 2 A possible explanation for the lack of effect on the incidence of coronary heart disease could be unfavourable metabolic effects of the medication. Such unfavourable changes in serum lipids have been reported both from clinical trials3' and epidemiological studies.""-In the cardiovascular survey in Finnmark carried out in 1974-5k subjects who reported that they were having treatment for hypertension had higher cholesterol, triglycerides, and glucose than "healthy" subjects. These findings initiated a side project to the cardiovascular survey in Finnmark 1977 where information was obtained on present and previous use of antihypertensive drugs. In this paper we compare serum lipid concentrations in current users, previous users, and never users of such medication.
Methods and material
All subjects aged 20-53 in four municipalities in Finnmark were invited to the screening. Of 6088 invited, 4878 (80. 1%) attended. The procedure and methods, except for high-density lipoprotein cholesterol (HDL-C) determination, were identical to those used in the former cardiovascular study in Finnmark and have been described elsewhere."2 At the screening specially trained interviewers asked 141 each subject the following two questions: "Do you use antihypertensive drugs?" and "Have you previously used antihypertensive drugs?" If the answer to any of these questions was "yes" the participant was asked which brand(s) was used. If the participant was a former user the year of stopping was recorded. All subjects currently using nitroglycerine, quinidine, digitalis, and drugs of unknown brands were excluded. The subjects were divided into those who used alprenolol, propranolol, and pindolol (betablockers) and those who used hydrochlorthiazide, trichlormethiazide, and polythiazide (thiazides) and clonidine, chlorthalidone, and frusemide (called other). Subjects using antihypertensive drugs had significantly lower HDL-C and relative HDL-C compared both with previous and never users (p<001). These differences remained significant after adjustment for relative weight. Between users of different drug categories and between previous users and never users no such differences were observed. There was a trend towards higher cholesterol, triglyceride, and glucose levels in users, but those differences were not statistically significant. The material was also analysed for cigarette smokers and non-smokers separately. This analysis showed larger differences as the z-values for HDL-C in smokers were -0-73, -0-01, and -0-01 for the users, previous users, and never users respectively (p<0.005). Among the non-smokers the HDL-C differences were somewhat reduced (-0.36, -0-08, and 0-07, respectively) but remained significant between the users and never users (p<001). There was a statistically significant difference between smoking and non-smoking drug users (p<002). For the other variables, except for relative HDL-C which followed the HDL-C, the analysis within smoking categories showed the same pattern as for the total group.
Discussion
In cross-sectional studies one can never completely rule out the possibility that the observed differences are caused by selection bias and confounding variables rather than particular treatment. In the present study, however, a considerable part of the bias appears to have been removed by the use of a blood pressure matched control group. All never users of antihypertensive drugs, adjusted for age and sex (z = 0, SD = 1), differ clearly in total cholesterol from the drug users (z = 0-27, p<001). On the other hand, the control group had a small (z = 0-22) Confounding factors may remain in this study even after the blood pressure matching. A few variables have been explicitly examined from this point of view. For instance, the analysis within smoking categories gave larger differences, indicating an interaction between antihypertensive medication and cigarette smoking. Adjustment for relative weight reduced the differences somewhat but not enough to alter the significance of the findings. One must, however, keep in mind the potential effect of alcohol consumption and physical activity has not been controlled for in the present analysis. An indication of remaining confounding factors may be the similarity between users of different drug categories, which was surprising on the background of the diversity in chemical composition and mode of action of those drugs. In variables other than cholesterol the blood pressure matching had a much smaller effect, especially in HDL-C where the matched never users had a z-value close to the total group of never users. In addition HDL-C was the only variable where drug users differ most from never users. A reduced HDL-C in users of beta-blockers has been seen in other studies, 45 11 whereas a similar effect of thiazide has not been reported. Helgeland et al4 reported no significant difference in HDL-C between thiazide users and controls and neither did Grimm et al7 in a double-blind crossover study. In the LRC study" a trend in the opposite direction toward higher HDL-C in thiazide users was observed, especially for women. For total cholesterol no statistically significant differences were observed in users, previous users, and matched never users. These results are in accordance with other reports that show none or minor changes in total cholesterol35 7-8 for most antihypertensive drugs.
The difference in HDL-C between smokers and non-smokers was much larger in drug users than among never users. This interaction may indicate use of stronger indications for antihypertensive medication among smokers. Drug users had altogether the most unfavourable level for all the compared variables in the present study. If the observed differences in serum lipids are caused by the drug use the unfavourable effect may be large enough to outweigh a beneficial effect of blood pressure reduction on the incidence of coronary heart disease. 
